Tables, named ranges, line breaks, modern functions, and helper columns make Excel formulas easier to read, audit, and fix.

Life is hectic, and juggling dozens of apps for the "must-do" chores adds to the noise. Since I already work in Excel daily, ...

If you watched and liked Stranger Things‘ first four seasons, you’re obviously going to watch its last. That won’t change no matter what I say about Stranger Things 5 Volume One. So your interest in ...

Durham leaders have approved a rezoning request that will allow Research Triangle Park to become more of a destination hub. Durham County Board of Commissioners voted unanimously on Monday to amend ...

Shares of Agios Pharmaceuticals AGIO tanked about 51% on Wednesday after it reported mixed top-line results from the phase III RISE UP study, which evaluated orally administered Pyrukynd (mitapivat) ...

Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ongoing trial of a regenerative cell therapy for Parkinson’s disease. The ...

Nov 19 (Reuters) - Agios Pharmaceuticals (AGIO.O), opens new tab said on Wednesday its sickle cell disease drug met one of its two main goals in a late-stage study of patients aged 16 and older but ...

For weeks, biotech investors have been bracing for the results of a large, late-stage trial of Agios Pharmaceuticals Pyrukynd pill in patients with sickle cell disease.

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. Down the line, Adagene could make up to $840 million in development and commercial ...

Mayo Clinic researchers have developed a pioneering method to mend damaged hearts without open-heart surgery, an advance that could one day transform the treatment of heart failure. The new approach ...